Skip to main content

CORRECTION article

Front. Mol. Biosci., 30 August 2021
Sec. Molecular Diagnostics and Therapeutics
This article is part of the Research Topic Interventional Therapy of Hepatocellular Carcinoma View all 14 articles

Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib

Lei Zhang&#x;Lei Zhang1Zhi-Ping Yan,,&#x;Zhi-Ping Yan2,3,4Zhong-Heng Hou&#x;Zhong-Heng Hou1Peng Huang&#x;Peng Huang1Min-Jie Yang,,Min-Jie Yang2,3,4Shuai ZhangShuai Zhang1Shen ZhangShen Zhang1Shao-Hua ZhangShao-Hua Zhang5Xiao-Li Zhu&#x;Xiao-Li Zhu1Cai-Fang Ni&#x;Cai-Fang Ni1Qiang Li
&#x;Qiang Li6*
  • 1Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China
  • 2Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China
  • 3Shanghai Institution of Medical Imaging, Shanghai, China
  • 4National Clinical Research Center for Interventional Medicine, Shanghai, China
  • 5Institute of Urology, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen, China
  • 6Department of Radiology, The Affiliated People’s Hospital of Ningbo University, Ningbo, China

A Corrigendum on
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib

by Zhang, L., Yan, Z.-P., Hou, Z.-H., Huang, P., Yang, M.-J., Zhang, S., Zhang, S., Zhang, S.-H., Zhu, X.-L., Ni, C.-F., and, Li, Q (2021). Front. Mol. Biosci. 8:624366. doi: 10.3389/fmolb.2021.624366

In the published article, there was an error regarding the affiliations for Lei Zhang and Cai-Fang Ni. One of the affiliations was added in error. This has now been removed.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: TACE, sorafenib, HCC, platelet count, neutrophils, lymphocytes

Citation: Zhang L, Yan Z-P, Hou Z-H, Huang P, Yang M-J, Zhang S, Zhang S, Zhang S-H, Zhu X-L, Ni C-F and Li Q (2021) Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib. Front. Mol. Biosci. 8:727969. doi: 10.3389/fmolb.2021.727969

Received: 20 June 2021; Accepted: 30 July 2021;
Published: 30 August 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Zhang, Yan, Hou, Huang, Yang, Zhang, Zhang, Zhang, Zhu, Ni and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Qiang Li, rmliqiang@nbu.edu.cn

These authors have contributed equally to this work and share first authorship

These authors have contributed equally

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.